ALX ONCOLOGY HOLDINGS INC
ALXONASDAQTrading Snapshot
- Day Range
- $1.12 – $1.34
- 52-Week Range
- $0.86 – $2.66
- Volume (shares)
- 1,532,604
- Avg Volume (shares)
- —
- Shares Outstanding
- 138.3M
- Next Earnings
- 2026-11-06
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -1.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.60
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.8%
ALX ONCOLOGY HOLDINGS INC
ALXO
StockOtter · stockotter.spaceAbout ALX ONCOLOGY HOLDINGS INC
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-po
7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc.
BlackRock Inc. bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bough
ALX Oncology to Present at Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat
5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO
5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer